You are here
- Home
- Therapy Areas
Gastrointestinal
The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 40 mg Esomeprazole Administered Orally and Intravenously as a 15 minute infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects with Symptoms of Gastroesophageal Reflux Disease (GERD
- collapse A randomised, double-blind, multicentre, phase III study to evaluate safety of esomeprazole 40 mg given i.v. or orally o.d. for 1 week to subjects with erosive reflux oesophagitis, followed by 3 weeks' open oral treatment with esomeprazole 40 mg o.d.
- collapse A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40 mg qd and 20 mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated with Daily NSAID Use in Patients at Risk
- collapse A Comparative Efficacy and Safety Study of Nexium (esomeprazole magnesium) Delayed-Release Capsules (40mg qd and 20mg qd) versus Placebo for the Prevention of Gastric Ulcers Associated with Daily NSAID Use in Patients at Risk
- collapse Ulcer GU IV (discont NSAID)
- collapse Ulcer GU III (discont NSAID)
- collapse A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40 mg qd and 20 mg qd) versus Ranitidine 150 mg bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued
- collapse A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40 mg qd and 20 mg qd) versus Ranitidine 150 mg bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued
- collapse Efficacy of esomeprazole 40mg q.d. versus placebo and esomeprazole 20mg q.d. versus placebo in treatment for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs
- collapse Efficacy of esomeprazle 40mg Once Daily versus placebo and exomeprazole 20mg Once Daily versus placebo in treatment for relief of upper GI symptoms associated with continuous use of NSAIDS including COX-2 selective NSAIDS
